<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="bold;} span.year {font-family : courier ; font-style : italic;} Allergy" exact="Asthma" post="Immunol ResAllergy Asthma Immunol ResAAIRAllergy, Asthma &amp;amp; Immunology Research2092-73552092-7363The"/>
 <result pre=": courier ; font-style : italic;} Allergy Asthma Immunol ResAllergy" exact="Asthma" post="Immunol ResAAIRAllergy, Asthma &amp;amp; Immunology Research2092-73552092-7363The Korean Academy of"/>
 <result pre="font-style : italic;} Allergy Asthma Immunol ResAllergy Asthma Immunol ResAAIRAllergy," exact="Asthma" post="&amp;amp; Immunology Research2092-73552092-7363The Korean Academy of Asthma, Allergy and"/>
 <result pre="of Asthma, Allergy and Clinical Immunology; The Korean Academy of" exact="Pediatric" post="Allergy and Respiratory Disease pmcid: 7346995 pmid: 32638559 doi:"/>
 <result pre="and Clinical Immunology; The Korean Academy of Pediatric Allergy and" exact="Respiratory" post="Disease pmcid: 7346995 pmid: 32638559 doi: 10.4168/aair.2020.12.5.783 : Review"/>
 <result pre="Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory" exact="Disease" post="pmcid: 7346995 pmid: 32638559 doi: 10.4168/aair.2020.12.5.783 : Review Management"/>
 <result pre="pmcid: 7346995 pmid: 32638559 doi: 10.4168/aair.2020.12.5.783 : Review Management of" exact="Allergic" post="Patients During the COVID-19 Pandemic in Asia https://orcid.org/0000-0002-0760-0071LeeJae-Hyun1https://orcid.org/0000-0001-8918-9353LeeYoungsoo2https://orcid.org/0000-0001-7276-8519LeeSuh-Young3https://orcid.org/0000-0002-6308-2045Van BeverHugo4https://orcid.org/0000-0002-8553-812XLouHongfei56https://orcid.org/0000-0002-0910-9884ZhangLuo567https://orcid.org/0000-0003-2614-0303ParkHae-Sim2[1],"/>
 <result pre="Asthma, Allergy and Clinical Immunology â€¢ The Korean Academy of" exact="Pediatric" post="Allergy and Respiratory Disease, 2020This is an Open Access"/>
 <result pre="Clinical Immunology â€¢ The Korean Academy of Pediatric Allergy and" exact="Respiratory" post="Disease, 2020This is an Open Access article distributed under"/>
 <result pre="provided the original work is properly cited. Abstract Although a" exact="viral infection" post="is a major triggering factor of asthma and allergic"/>
 <result pre="the original work is properly cited. Abstract Although a viral" exact="infection" post="is a major triggering factor of asthma and allergic"/>
 <result pre="Although a viral infection is a major triggering factor of" exact="asthma" post="and allergic diseases, asthma is suggested to be not"/>
 <result pre="is a major triggering factor of asthma and allergic diseases," exact="asthma" post="is suggested to be not a predisposing condition for"/>
 <result pre="is suggested to be not a predisposing condition for coronavirus" exact="disease" post="2019 (COVID-19) infection. However, patients with severe asthma/allergic disease"/>
 <result pre="coronavirus disease 2019 (COVID-19) infection. However, patients with severe asthma/allergic" exact="disease" post="requiring systemic corticosteroids or immunosuppressive agents may be at"/>
 <result pre="2019 (COVID-19) infection. However, patients with severe asthma/allergic disease requiring" exact="systemic" post="corticosteroids or immunosuppressive agents may be at higher risk"/>
 <result pre="at higher risk of more severe clinical course of this" exact="infectious disease." post="For allergic patients who have been followed up at"/>
 <result pre="For allergic patients who have been followed up at an" exact="allergy" post="clinic in our region, it is recommended that they"/>
 <result pre="region, it is recommended that they (patients with asthma, rhinitis," exact="atopic dermatitis" post="or chronic urticaria) continue to receive maintenance therapy and"/>
 <result pre="it is recommended that they (patients with asthma, rhinitis, atopic" exact="dermatitis" post="or chronic urticaria) continue to receive maintenance therapy and"/>
 <result pre="is recommended that they (patients with asthma, rhinitis, atopic dermatitis" exact="or chronic" post="urticaria) continue to receive maintenance therapy and be in"/>
 <result pre="recommended that they (patients with asthma, rhinitis, atopic dermatitis or" exact="chronic" post="urticaria) continue to receive maintenance therapy and be in"/>
 <result pre="status. Patients who have used biologics (currently available for targeting" exact="type 2" post="inflammation) and allergen immunotherapy should continue the treatment while"/>
 <result pre="decisions under the urgent situation in Asia. Coronavirus pandemics Asia" exact="allergy" post="and immunology asthma rhinitis atopic dermatitis chronic urticaria management"/>
 <result pre="urgent situation in Asia. Coronavirus pandemics Asia allergy and immunology" exact="asthma" post="rhinitis atopic dermatitis chronic urticaria management immunotherapy Funding Korea"/>
 <result pre="situation in Asia. Coronavirus pandemics Asia allergy and immunology asthma" exact="rhinitis" post="atopic dermatitis chronic urticaria management immunotherapy Funding Korea Health"/>
 <result pre="in Asia. Coronavirus pandemics Asia allergy and immunology asthma rhinitis" exact="atopic dermatitis" post="chronic urticaria management immunotherapy Funding Korea Health Industry Development"/>
 <result pre="Asia. Coronavirus pandemics Asia allergy and immunology asthma rhinitis atopic" exact="dermatitis" post="chronic urticaria management immunotherapy Funding Korea Health Industry Development"/>
 <result pre="Coronavirus pandemics Asia allergy and immunology asthma rhinitis atopic dermatitis" exact="chronic" post="urticaria management immunotherapy Funding Korea Health Industry Development Institutehttps://doi.org/10.13039/501100003710"/>
 <result pre="pandemics Asia allergy and immunology asthma rhinitis atopic dermatitis chronic" exact="urticaria" post="management immunotherapy Funding Korea Health Industry Development Institutehttps://doi.org/10.13039/501100003710 HI16C0992"/>
 <result pre="Funding Korea Health Industry Development Institutehttps://doi.org/10.13039/501100003710 HI16C0992 INTRODUCTION The coronavirus" exact="disease" post="2019 (COVID-19) outbreak has started from Wuhan in China"/>
 <result pre="the World Health Organization (WHO) named this new coronavirus severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of"/>
 <result pre="World Health Organization (WHO) named this new coronavirus severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). The first case of person-to-person"/>
 <result pre="Health Organization (WHO) named this new coronavirus severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). The first case of person-to-person transmission"/>
 <result pre="Korea, 2.5% in Japan and 0.1% in Singapore, which is" exact="lower" post="than in the US and European countries.2 Higher mortality"/>
 <result pre="in elderly patients and patients with comorbid conditions such as" exact="hypertension" post="and metabolic diseases.13 In addition, an important issue is"/>
 <result pre="In addition, an important issue is the spreading of this" exact="infection" post="to healthcare workers (HCWs). In China, 3.8% of the"/>
 <result pre="were reported in Wuhan.4 The prevalence of allergic diseases, including" exact="asthma" post="and allergic rhinitis (AR), is increasing in Asian countries,"/>
 <result pre="in Wuhan.4 The prevalence of allergic diseases, including asthma and" exact="allergic rhinitis" post="(AR), is increasing in Asian countries, especially in the"/>
 <result pre="Wuhan.4 The prevalence of allergic diseases, including asthma and allergic" exact="rhinitis" post="(AR), is increasing in Asian countries, especially in the"/>
 <result pre="increasing in Asian countries, especially in the elderly,56 in which" exact="viral" post="infections are major triggering factors. Although the initial starting"/>
 <result pre="in Asian countries, especially in the elderly,56 in which viral" exact="infections" post="are major triggering factors. Although the initial starting point"/>
 <result pre="how to protect HCWs. To prevent the spread of this" exact="viral infection," post="the specified preventive measures have been applied to the"/>
 <result pre="washing, maintaining a social distance of 2 m and practicing" exact="respiratory" post="hygiene for the public.9 During the COVID-19 pandemic, hospital"/>
 <result pre="symptoms and temperatures during their stay in the hospital. The" exact="American" post="Centers for Disease Control and Prevention (CDC) recommended appropriate"/>
 <result pre="during their stay in the hospital. The American Centers for" exact="Disease" post="Control and Prevention (CDC) recommended appropriate personal protective equipment"/>
 <result pre="respirators and goggles.110 THE RISK OF COVID-19 IN PATIENTS WITH" exact="ASTHMA" post="AND ALLERGIC DISEASES Although a respiratory viral infection is"/>
 <result pre="COVID-19 IN PATIENTS WITH ASTHMA AND ALLERGIC DISEASES Although a" exact="respiratory" post="viral infection is a major contributing factor to asthma"/>
 <result pre="IN PATIENTS WITH ASTHMA AND ALLERGIC DISEASES Although a respiratory" exact="viral infection" post="is a major contributing factor to asthma exacerbation as"/>
 <result pre="PATIENTS WITH ASTHMA AND ALLERGIC DISEASES Although a respiratory viral" exact="infection" post="is a major contributing factor to asthma exacerbation as"/>
 <result pre="a respiratory viral infection is a major contributing factor to" exact="asthma" post="exacerbation as well as a triggering factor, information about"/>
 <result pre="a triggering factor, information about the influence of SARS-CoV-2 on" exact="asthma" post="and allergic diseases is limited. It was reported that"/>
 <result pre="were hospitalized due to confirmed COVID-19 in Wuhan, China had" exact="asthma" post="or other allergic diseases such as AR, atopic dermatitis"/>
 <result pre="China had asthma or other allergic diseases such as AR," exact="atopic dermatitis" post="(AD) and food allergy.11 Drug hypersensitivity and urticaria were"/>
 <result pre="had asthma or other allergic diseases such as AR, atopic" exact="dermatitis" post="(AD) and food allergy.11 Drug hypersensitivity and urticaria were"/>
 <result pre="such as AR, atopic dermatitis (AD) and food allergy.11 Drug" exact="hypersensitivity" post="and urticaria were found in 11.4% and 1.4% of"/>
 <result pre="AR, atopic dermatitis (AD) and food allergy.11 Drug hypersensitivity and" exact="urticaria" post="were found in 11.4% and 1.4% of the patients,"/>
 <result pre="COVID-19 remain unclear. Another report from Wuhan observed a markedly" exact="lower" post="prevalence of asthma (5 asthmatics among 548 patients with"/>
 <result pre="Another report from Wuhan observed a markedly lower prevalence of" exact="asthma" post="(5 asthmatics among 548 patients with confirmed COVID-19, 0.9%)"/>
 <result pre="patients with confirmed COVID-19, 0.9%) compared to the prevalence of" exact="adult" post="asthma in Wuhan (6.4%).12 In another recent study of"/>
 <result pre="with confirmed COVID-19, 0.9%) compared to the prevalence of adult" exact="asthma" post="in Wuhan (6.4%).12 In another recent study of the"/>
 <result pre="the 22 patients who died of COVID-19 were suffering from" exact="asthma" post="or other allergic diseases.3 However, the possibility of under-diagnosis"/>
 <result pre="in those studies. Although it has not been determined whether" exact="allergy" post="or asthma may predispose patients to COVID-19, non-pandemic coronavirus"/>
 <result pre="studies. Although it has not been determined whether allergy or" exact="asthma" post="may predispose patients to COVID-19, non-pandemic coronavirus infections have"/>
 <result pre="allergy or asthma may predispose patients to COVID-19, non-pandemic coronavirus" exact="infections" post="have aggravated asthma both in adults and children.141516 Thus,"/>
 <result pre="may predispose patients to COVID-19, non-pandemic coronavirus infections have aggravated" exact="asthma" post="both in adults and children.141516 Thus, the probability of"/>
 <result pre="adults and children.141516 Thus, the probability of the aggravation of" exact="asthma" post="and other allergic diseases by COVID-19 should be considered."/>
 <result pre="by COVID-19 should be considered. Furthermore, as pediatric patients with" exact="asthma" post="are at higher risk of respiratory viral infections, most"/>
 <result pre="as pediatric patients with asthma are at higher risk of" exact="respiratory" post="viral infections, most experts advise extreme caution in such"/>
 <result pre="pediatric patients with asthma are at higher risk of respiratory" exact="viral" post="infections, most experts advise extreme caution in such cases.17"/>
 <result pre="frequently used to achieve a well-controlled status in patients with" exact="asthma" post="or severe allergic diseases. Systemic corticosteroid, one of the"/>
 <result pre="well-controlled status in patients with asthma or severe allergic diseases." exact="Systemic" post="corticosteroid, one of the most widely used rescue medications"/>
 <result pre="in allergic diseases, is known to increase the risk for" exact="systemic" post="infections, and so do other immunosuppressive agents such as"/>
 <result pre="antibodies, has improved treatment outcomes with reduction in medications including" exact="systemic" post="corticosteroids. As it is not clear whether biologics may"/>
 <result pre="As it is not clear whether biologics may increase the" exact="susceptibility to" post="serious infections, further studies are needed to draw conclusions."/>
 <result pre="and sublingual immunotherapy (SLIT), is widely applied to patients with" exact="asthma" post="or AR in Asia.19202122 AIT, especially SCIT, requires long-term"/>
 <result pre="of exposure to the virus. To prevent the risk of" exact="infection" post="and to provide safe medical services, the following control"/>
 <result pre="measures have been suggested to patients undergoing SCIT in each" exact="allergy" post="center.23 Whenever the patients visit the hospital, they should"/>
 <result pre="Any confirmed cases of COVID-19 should stop AIT until this" exact="infection" post="completely resolves and the viral test result becomes negative.23"/>
 <result pre="should stop AIT until this infection completely resolves and the" exact="viral" post="test result becomes negative.23 A good piece of advice"/>
 <result pre="anti-fog protective goggles and protective face shields, is required in" exact="allergy" post="centers in Beijing. Injections for SCIT should be modified"/>
 <result pre="discontinuation of SCIT is recommended if regular visits to the" exact="allergy" post="center are difficult. Re-initiation can be planned until continuous"/>
 <result pre="the need for patients to visit or stay in an" exact="allergy" post="center during the COVID-19 pandemic. PHARMACOLOGIC TREATMENT Asthma (adult"/>
 <result pre="in an allergy center during the COVID-19 pandemic. PHARMACOLOGIC TREATMENT" exact="Asthma" post="(adult and childhood) and AR It is well known"/>
 <result pre="known that common coronaviruses are associated with the worsening of" exact="asthma" post="symptoms.1415 Recent reports have suggested that asthma does not"/>
 <result pre="the worsening of asthma symptoms.1415 Recent reports have suggested that" exact="asthma" post="does not increase the risk of COVID-19 infection or"/>
 <result pre="suggested that asthma does not increase the risk of COVID-19" exact="infection" post="or related complications.31113 However, these data have been obtained"/>
 <result pre="has not yet been accurately determined. The WHO recommends avoiding" exact="systemic" post="steroid use in patients with COVID-19 (not limited to"/>
 <result pre="recommends avoiding systemic steroid use in patients with COVID-19 (not" exact="limited" post="to asthmatic patients), except in some situations such as"/>
 <result pre="limited to asthmatic patients), except in some situations such as" exact="septic shock" post="and acute respiratory distress syndrome.11242526 All asthmatic patients should"/>
 <result pre="patients), except in some situations such as septic shock and" exact="acute" post="respiratory distress syndrome.11242526 All asthmatic patients should be treated"/>
 <result pre="except in some situations such as septic shock and acute" exact="respiratory" post="distress syndrome.11242526 All asthmatic patients should be treated with"/>
 <result pre="long-acting beta2-agonists as controllers according to the Global Initiative for" exact="Asthma" post="(GINA) guidelines.27 It would be better to use a"/>
 <result pre="of the virus via the device.28 If patients with mild-to-moderate" exact="asthma" post="are well controlled and have sufficient maintenance medications, it"/>
 <result pre="efforts should be made to reduce the prescribed dose of" exact="systemic" post="corticosteroids in order to avoid an immuno-compromised status in"/>
 <result pre="status in the management of severe asthma. Elderly patients with" exact="asthma" post="or comorbid conditions should be more strictly monitored. Additionally,"/>
 <result pre="replacement treatment be maintained in asthmatic patients with IgG subclass" exact="deficiency" post="suffering from frequent asthma exacerbations.30 Such patients should receive"/>
 <result pre="in asthmatic patients with IgG subclass deficiency suffering from frequent" exact="asthma" post="exacerbations.30 Such patients should receive IgG replacement treatment during"/>
 <result pre="to the virus during their visits in order to prevent" exact="asthma" post="exacerbation.31 Taken together, it is important to maintain each"/>
 <result pre="to step-down controller medications that are maintained.2932 If patients have" exact="asthma" post="exacerbations, they should be managed according to the GINA"/>
 <result pre="control status, the clinical necessity and potential risk of droplet" exact="infection" post="are compared carefully based on the judgment of the"/>
 <result pre="children than in adults.35 Moreover, according to data from the" exact="American" post="CDC, it is found that the prevalence of asthma"/>
 <result pre="the American CDC, it is found that the prevalence of" exact="asthma" post="in children (n = 345) with COVID-19 is about"/>
 <result pre="(n = 345) with COVID-19 is about 11.5%, which is" exact="lower" post="than that in the general population (20%). However, these"/>
 <result pre="However, these data must be interpreted with caution because the" exact="total" post="number of children included in the study was relatively"/>
 <result pre="guidelines. In addition, there is no evidence that currently available" exact="asthma" post="and allergy medications, including antihistamines, ICSs and bronchodilators, increase"/>
 <result pre="addition, there is no evidence that currently available asthma and" exact="allergy" post="medications, including antihistamines, ICSs and bronchodilators, increase the risk"/>
 <result pre="medications, including antihistamines, ICSs and bronchodilators, increase the risk of" exact="disease" post="exacerbation by COVID-19. It is also not advisable to"/>
 <result pre="not advisable to stop oral steroids in the management of" exact="asthma" post="if the patient is already taking these medications or"/>
 <result pre="or to avoid oral steroids for the treatment of an" exact="acute" post="asthma attack even if it is due to COVID-19.31"/>
 <result pre="to avoid oral steroids for the treatment of an acute" exact="asthma" post="attack even if it is due to COVID-19.31 Although"/>
 <result pre="asthma, it seems that COVID-19 is not a risk for" exact="asthma" post="exacerbation in healthy or asthmatic children. During the current"/>
 <result pre="the effect of COVID-19 on AR in children yet. The" exact="Allergic" post="Rhinitis and its Impact on Asthma (ARIA)-European Academy of"/>
 <result pre="effect of COVID-19 on AR in children yet. The Allergic" exact="Rhinitis" post="and its Impact on Asthma (ARIA)-European Academy of Allergology"/>
 <result pre="in children yet. The Allergic Rhinitis and its Impact on" exact="Asthma" post="(ARIA)-European Academy of Allergology and Clinical Immunology (EAACI) mentioned"/>
 <result pre="symptoms or seem to be at increased risk of severe" exact="disease" post="when infected with COVID-19.37 Atopic dermatitis AD is a"/>
 <result pre="at increased risk of severe disease when infected with COVID-19.37" exact="Atopic dermatitis" post="AD is a chronic inflammatory skin disease characterized by"/>
 <result pre="increased risk of severe disease when infected with COVID-19.37 Atopic" exact="dermatitis" post="AD is a chronic inflammatory skin disease characterized by"/>
 <result pre="disease when infected with COVID-19.37 Atopic dermatitis AD is a" exact="chronic" post="inflammatory skin disease characterized by recurrent eczematous skin lesions"/>
 <result pre="infected with COVID-19.37 Atopic dermatitis AD is a chronic inflammatory" exact="skin disease" post="characterized by recurrent eczematous skin lesions and pruritus. Not"/>
 <result pre="with COVID-19.37 Atopic dermatitis AD is a chronic inflammatory skin" exact="disease" post="characterized by recurrent eczematous skin lesions and pruritus. Not"/>
 <result pre="dermatitis AD is a chronic inflammatory skin disease characterized by" exact="recurrent" post="eczematous skin lesions and pruritus. Not only is AD"/>
 <result pre="Not only is AD associated with airway diseases such as" exact="asthma" post="and AR, but patients with severe AD are also"/>
 <result pre="with severe AD are also likely to be vulnerable to" exact="respiratory" post="infections because of their systemic immunosuppressive treatment.38 However, discontinuation"/>
 <result pre="severe AD are also likely to be vulnerable to respiratory" exact="infections" post="because of their systemic immunosuppressive treatment.38 However, discontinuation of"/>
 <result pre="likely to be vulnerable to respiratory infections because of their" exact="systemic" post="immunosuppressive treatment.38 However, discontinuation of immunosuppressive agents should not"/>
 <result pre="lead to the aggravation of AD and even to disseminated" exact="viral" post="skin diseases such as eczema herpeticum.39 Maintenance of skin"/>
 <result pre="to the aggravation of AD and even to disseminated viral" exact="skin diseases" post="such as eczema herpeticum.39 Maintenance of skin hygiene and"/>
 <result pre="AD and even to disseminated viral skin diseases such as" exact="eczema" post="herpeticum.39 Maintenance of skin hygiene and the use of"/>
 <result pre="would be preferable options in the treatment of AD. However," exact="systemic" post="immunosuppressant or immune-modulating agents, such as dupilumab, seem unlikely"/>
 <result pre="the basis of physicians' judgment to prevent flares of AD." exact="Chronic" post="urticaria (CU) and drug allergy CU is defined as"/>
 <result pre="basis of physicians' judgment to prevent flares of AD. Chronic" exact="urticaria" post="(CU) and drug allergy CU is defined as urticaria"/>
 <result pre="judgment to prevent flares of AD. Chronic urticaria (CU) and" exact="drug allergy" post="CU is defined as urticaria that has been present"/>
 <result pre="to prevent flares of AD. Chronic urticaria (CU) and drug" exact="allergy" post="CU is defined as urticaria that has been present"/>
 <result pre="Chronic urticaria (CU) and drug allergy CU is defined as" exact="urticaria" post="that has been present for at least 6 weeks"/>
 <result pre="In particular, older patients with comorbidities, such as hypertension, diabetes," exact="cardiovascular disease" post="and chronic respiratory disease, are vulnerable to infections and"/>
 <result pre="particular, older patients with comorbidities, such as hypertension, diabetes, cardiovascular" exact="disease" post="and chronic respiratory disease, are vulnerable to infections and"/>
 <result pre="patients with comorbidities, such as hypertension, diabetes, cardiovascular disease and" exact="chronic" post="respiratory disease, are vulnerable to infections and are more"/>
 <result pre="with comorbidities, such as hypertension, diabetes, cardiovascular disease and chronic" exact="respiratory" post="disease, are vulnerable to infections and are more cautious"/>
 <result pre="diabetes, cardiovascular disease and chronic respiratory disease, are vulnerable to" exact="infections" post="and are more cautious in visiting hospitals.4243 However, visiting"/>
 <result pre="symptoms. Patients are required to follow all the policies for" exact="infection" post="control. Physicians should delay the evaluation of the causes"/>
 <result pre="reschedule patient outpatient visits until the pandemic is over. Drug" exact="allergy" post="can be managed according to similar basic principles. Drug"/>
 <result pre="allergy can be managed according to similar basic principles. Drug" exact="allergy" post="should be immediately treated especially in the presence of"/>
 <result pre="in the presence of symptoms, such as generalized urticaria, angioedema," exact="bronchospasm" post="and hypotension. Epinephrine injection is contemplated in cases of"/>
 <result pre="is actively considered in patients who need immediate administration of" exact="hypersensitivity" post="drugs. In principle, desensitization needs to be performed in"/>
 <result pre="needs to be performed in the hospital according to the" exact="infection" post="control procedure.44 BIOLOGIC TREATMENT Regular administration of biologics, such"/>
 <result pre="anti-IgE antibodies, has become a common treatment option for severe" exact="asthma" post="as well as for uncontrolled cases of CU and"/>
 <result pre="common treatment option for severe asthma as well as for" exact="uncontrolled" post="cases of CU and AD. It is critical to"/>
 <result pre="cases of CU and AD. It is critical to control" exact="disease" post="activity through the prevention of exacerbations.45 In addition, there"/>
 <result pre="dosage of biologics scheduled.29 However, most of the biologics require" exact="periodic" post="parenteral/subcutaneous administration, for which such patients have to visit"/>
 <result pre="parenteral/subcutaneous administration, for which such patients have to visit an" exact="allergy" post="clinic to receive medications according to a treatment protocol."/>
 <result pre="allergic children, biologics are mainly used in patients with severe" exact="eczema" post="or severe asthma. There have been no studies or"/>
 <result pre="is still uncertain whether COVID-19 increases the risk of aggravating" exact="asthma" post="or allergic diseases. Detailed monitoring and optimal treatment with"/>
 <result pre="biologics need to be continued in all patients suffering from" exact="asthma" post="and allergic diseases. This can be achieved in a"/>
 <result pre="[Internet]GenevaWHO2020cited 2020 May 25Available from: https://covid19.who.int/ 3collab: Korean Society of" exact="Infectious" post="Diseasescollab: Korean Society of Pediatric Infectious Diseasescollab: Korean Society"/>
 <result pre="https://covid19.who.int/ 3collab: Korean Society of Infectious Diseasescollab: Korean Society of" exact="Pediatric" post="Infectious Diseasescollab: Korean Society of Epidemiologycollab: Korean Society for"/>
 <result pre="3collab: Korean Society of Infectious Diseasescollab: Korean Society of Pediatric" exact="Infectious" post="Diseasescollab: Korean Society of Epidemiologycollab: Korean Society for Antimicrobial"/>
 <result pre="Epidemiologycollab: Korean Society for Antimicrobial Therapycollab: Korean Society for Healthcare-associated" exact="Infection" post="Control and Preventioncollab: Korea Centers for Disease Control and"/>
 <result pre="Society for Healthcare-associated Infection Control and Preventioncollab: Korea Centers for" exact="Disease" post="Control and PreventionReport on the epidemiological feature of coronavirus"/>
 <result pre="Disease Control and PreventionReport on the epidemiological feature of coronavirus" exact="disease" post="2019 (COVID-19) Outbreak in the Republic of Korea from"/>
 <result pre="Med Sci202035e11232174069 4WuZMcGooganJMCharacteristics of and important lesson from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA202032312391242 5ParkSYKimJHKimHJSeoBKwonOYChangHSet al.High prevalence of asthma in"/>
 <result pre="Center for Disease Control and PreventionJAMA202032312391242 5ParkSYKimJHKimHJSeoBKwonOYChangHSet al.High prevalence of" exact="asthma" post="in elderly women: findings from a Korean national health"/>
 <result pre="elderly women: findings from a Korean national health database and" exact="adult" post="asthma cohortAllergy Asthma Immunol Res20181038739629949835 6ZhangYZhangLIncreasing prevalence of allergic"/>
 <result pre="women: findings from a Korean national health database and adult" exact="asthma" post="cohortAllergy Asthma Immunol Res20181038739629949835 6ZhangYZhangLIncreasing prevalence of allergic rhinitis"/>
 <result pre="from a Korean national health database and adult asthma cohortAllergy" exact="Asthma" post="Immunol Res20181038739629949835 6ZhangYZhangLIncreasing prevalence of allergic rhinitis in ChinaAllergy"/>
 <result pre="and adult asthma cohortAllergy Asthma Immunol Res20181038739629949835 6ZhangYZhangLIncreasing prevalence of" exact="allergic rhinitis" post="in ChinaAllergy Asthma Immunol Res20191115616930661309 7XuSLiYBeware of the second"/>
 <result pre="adult asthma cohortAllergy Asthma Immunol Res20181038739629949835 6ZhangYZhangLIncreasing prevalence of allergic" exact="rhinitis" post="in ChinaAllergy Asthma Immunol Res20191115616930661309 7XuSLiYBeware of the second"/>
 <result pre="Asthma Immunol Res20181038739629949835 6ZhangYZhangLIncreasing prevalence of allergic rhinitis in ChinaAllergy" exact="Asthma" post="Immunol Res20191115616930661309 7XuSLiYBeware of the second wave of COVID-19Lancet20203951321132232277876"/>
 <result pre="Acad Sci U S A20201179241924332269081 9collab: World Health OrganizationWHO coronavirus" exact="disease" post="(COVID-19) advice for the public [Internet]GenevaWHO2020cited 2020 May 25Available"/>
 <result pre="public [Internet]GenevaWHO2020cited 2020 May 25Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public 10collab: Centers for" exact="Disease" post="Control and PreventionCoronavirus disease 2019 (COVID-19) situation summary [Internet]AtlantaCDC2020cited"/>
 <result pre="25Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public 10collab: Centers for Disease Control and PreventionCoronavirus" exact="disease" post="2019 (COVID-19) situation summary [Internet]AtlantaCDC2020cited 2020 May 25Available from:"/>
 <result pre="Wuhan, ChinaAllergyForthcoming2020 12LiXXuSYuMWangKTaoYZhouYet al.Risk factors for severity and mortality in" exact="adult" post="COVID-19 inpatients in WuhanJ Allergy Clin Immunol2020S0091-6749(20)30495-4 13GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical"/>
 <result pre="in WuhanJ Allergy Clin Immunol2020S0091-6749(20)30495-4 13GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med20203821708172032109013 14ZhengXYXuYJGuanWJLinLFRegional, age and"/>
 <result pre="ChinaN Engl J Med20203821708172032109013 14ZhengXYXuYJGuanWJLinLFRegional, age and respiratory-secretion-specific prevalence of" exact="respiratory" post="viruses associated with asthma exacerbation: a literature reviewArch Virol201816384585329327237"/>
 <result pre="14ZhengXYXuYJGuanWJLinLFRegional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with" exact="asthma" post="exacerbation: a literature reviewArch Virol201816384585329327237 15Van BeverHPChngSYGohDYChildhood severe acute"/>
 <result pre="with asthma exacerbation: a literature reviewArch Virol201816384585329327237 15Van BeverHPChngSYGohDYChildhood severe" exact="acute" post="respiratory syndrome, coronavirus infections and asthmaPediatr Allergy Immunol20041520620915209951 16GreenbergSBUpdate"/>
 <result pre="asthma exacerbation: a literature reviewArch Virol201816384585329327237 15Van BeverHPChngSYGohDYChildhood severe acute" exact="respiratory" post="syndrome, coronavirus infections and asthmaPediatr Allergy Immunol20041520620915209951 16GreenbergSBUpdate on"/>
 <result pre="literature reviewArch Virol201816384585329327237 15Van BeverHPChngSYGohDYChildhood severe acute respiratory syndrome, coronavirus" exact="infections" post="and asthmaPediatr Allergy Immunol20041520620915209951 16GreenbergSBUpdate on human rhinovirus and"/>
 <result pre="infectionsSemin Respir Crit Care Med20163755557127486736 17PapadopoulosNGChristodoulouIRohdeGAgacheIAlmqvistCBrunoAet al.Viruses and bacteria in" exact="acute" post="asthma exacerbations--a GA2 LEN-DARE systematic reviewAllergy20116645846821087215 18ChaudharyNSDonnellyJPMooreJXBaddleyJWSaffordMMWangHEAssociation of baseline"/>
 <result pre="Respir Crit Care Med20163755557127486736 17PapadopoulosNGChristodoulouIRohdeGAgacheIAlmqvistCBrunoAet al.Viruses and bacteria in acute" exact="asthma" post="exacerbations--a GA2 LEN-DARE systematic reviewAllergy20116645846821087215 18ChaudharyNSDonnellyJPMooreJXBaddleyJWSaffordMMWangHEAssociation of baseline steroid"/>
 <result pre="reviewAllergy20116645846821087215 18ChaudharyNSDonnellyJPMooreJXBaddleyJWSaffordMMWangHEAssociation of baseline steroid use with long-term rates of" exact="infection" post="and sepsis in the REGARDS cohortCrit Care20172118528701217 19RhyouHINamYHEfficacy of"/>
 <result pre="in the REGARDS cohortCrit Care20172118528701217 19RhyouHINamYHEfficacy of allergen immunotherapy for" exact="allergic asthma" post="in real world practiceAllergy Asthma Immunol Res2020129910931743967 20LouHHuangYOuyangYZhangYXiLChuXet al.Artemisia"/>
 <result pre="the REGARDS cohortCrit Care20172118528701217 19RhyouHINamYHEfficacy of allergen immunotherapy for allergic" exact="asthma" post="in real world practiceAllergy Asthma Immunol Res2020129910931743967 20LouHHuangYOuyangYZhangYXiLChuXet al.Artemisia"/>
 <result pre="of allergen immunotherapy for allergic asthma in real world practiceAllergy" exact="Asthma" post="Immunol Res2020129910931743967 20LouHHuangYOuyangYZhangYXiLChuXet al.Artemisia annua-sublingual immunotherapy for seasonal allergic"/>
 <result pre="22HuangYWangCCaoFZhaoYLouHZhangLComparison of long-term efficacy of subcutaneous immunotherapy in pediatric and" exact="adult" post="patients with allergic rhinitisAllergy Asthma Immunol Res201911687830479078 23KlimekLJutelMAkdisCBousquetJAkdisMBachertCet al.Handling"/>
 <result pre="subcutaneous immunotherapy in pediatric and adult patients with allergic rhinitisAllergy" exact="Asthma" post="Immunol Res201911687830479078 23KlimekLJutelMAkdisCBousquetJAkdisMBachertCet al.Handling of allergen immunotherapy in the"/>
 <result pre="the COVID-19 pandemic: An ARIA-EAACI statementAllergyForthcoming2020 24collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) situation report [Internet]GenevaWHO2020cited 2020 May 25Available from:"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA202032310611069 26collab: World Health OrganizationClinical management of"/>
 <result pre="in Wuhan, ChinaJAMA202032310611069 26collab: World Health OrganizationClinical management of severe" exact="acute" post="respiratory infection (SARI) when COVID-19 disease is suspected [Internet]GenevaWHO2020cited"/>
 <result pre="Wuhan, ChinaJAMA202032310611069 26collab: World Health OrganizationClinical management of severe acute" exact="respiratory" post="infection (SARI) when COVID-19 disease is suspected [Internet]GenevaWHO2020cited 2020"/>
 <result pre="ChinaJAMA202032310611069 26collab: World Health OrganizationClinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected [Internet]GenevaWHO2020cited 2020 May"/>
 <result pre="OrganizationClinical management of severe acute respiratory infection (SARI) when COVID-19" exact="disease" post="is suspected [Internet]GenevaWHO2020cited 2020 May 25Available from: https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf 27collab:"/>
 <result pre="27collab: Global Initiative for Asthma2019 GINA report, global strategy for" exact="asthma" post="management and prevention 2019 [Internet]FontanaGINA2019cited 2020 May 25Available from:"/>
 <result pre="serious, underappreciated riskCMAJ2020192E34632392488 29ShakerMSOppenheimerJGraysonMStukusDHartogNHsiehEWet al.COVID-19: pandemic contingency planning for the" exact="allergy" post="and immunology clinicJ Allergy Clin Immunol Pract2020814771488.e532224232 30KimJHYeYMBanGYShinYSLeeHYNamYHet al.Effects"/>
 <result pre="Allergy Clin Immunol Pract2020814771488.e532224232 30KimJHYeYMBanGYShinYSLeeHYNamYHet al.Effects of immunoglobulin replacement on" exact="asthma" post="exacerbation in adult asthmatics with IgG subclass deficiencyAllergy Asthma"/>
 <result pre="Pract2020814771488.e532224232 30KimJHYeYMBanGYShinYSLeeHYNamYHet al.Effects of immunoglobulin replacement on asthma exacerbation in" exact="adult" post="asthmatics with IgG subclass deficiencyAllergy Asthma Immunol Res2017952653328913992 31BroughHAKalayciOSedivaAUntersmayrEMunblitDRodriguez"/>
 <result pre="on asthma exacerbation in adult asthmatics with IgG subclass deficiencyAllergy" exact="Asthma" post="Immunol Res2017952653328913992 31BroughHAKalayciOSedivaAUntersmayrEMunblitDRodriguez Del RioPet al.Managing childhood allergies and"/>
 <result pre="IgG subclass deficiencyAllergy Asthma Immunol Res2017952653328913992 31BroughHAKalayciOSedivaAUntersmayrEMunblitDRodriguez Del RioPet al.Managing" exact="childhood" post="allergies and immunodeficiencies during respiratory virus epidemics - The"/>
 <result pre="subclass deficiencyAllergy Asthma Immunol Res2017952653328913992 31BroughHAKalayciOSedivaAUntersmayrEMunblitDRodriguez Del RioPet al.Managing childhood" exact="allergies" post="and immunodeficiencies during respiratory virus epidemics - The 2020"/>
 <result pre="Res2017952653328913992 31BroughHAKalayciOSedivaAUntersmayrEMunblitDRodriguez Del RioPet al.Managing childhood allergies and immunodeficiencies during" exact="respiratory" post="virus epidemics - The 2020 COVID-19 pandemic: a statement"/>
 <result pre="the EAACI-section on pediatricsPediatr Allergy ImmunolForthcoming2020 32JohnstonSLAsthma and COVID-19: is" exact="asthma" post="a risk factor for severe outcomes?AllergyForthcoming2020 33collab: American Thoracic"/>
 <result pre="COVID-19: is asthma a risk factor for severe outcomes?AllergyForthcoming2020 33collab:" exact="American" post="Thoracic SocietyPulmonary function laboratories: advice regarding COVID-19 [Internet]New YorkATS2020cited"/>
 <result pre="is asthma a risk factor for severe outcomes?AllergyForthcoming2020 33collab: American" exact="Thoracic" post="SocietyPulmonary function laboratories: advice regarding COVID-19 [Internet]New YorkATS2020cited 2020"/>
 <result pre="for asthma: a case-control studyJ Allergy Clin Immunol200411341541915007339 35LuXZhangLDuHZhangJLiYYQuJet al.SARS-CoV-2" exact="infection" post="in childrenN Engl J Med20203821663166532187458 36collab: CDC COVID-19 Response"/>
 <result pre="in childrenN Engl J Med20203821663166532187458 36collab: CDC COVID-19 Response TeamCoronavirus" exact="disease" post="2019 in Children â€&quot; United States, February 12â€&quot;April 2,"/>
 <result pre="February 12â€&quot;April 2, 2020MMWR Recomm Rep202069422426 37BousquetJAkdisCJutelMBachertCKlimekLAgacheIet al.Intranasal corticosteroids in" exact="allergic rhinitis" post="in COVID-19 infected patients: an ARIA-EAACI statementAllergyForthcoming2020 38SimonDWollenbergARenzHSimonHUAtopic dermatitis:"/>
 <result pre="12â€&quot;April 2, 2020MMWR Recomm Rep202069422426 37BousquetJAkdisCJutelMBachertCKlimekLAgacheIet al.Intranasal corticosteroids in allergic" exact="rhinitis" post="in COVID-19 infected patients: an ARIA-EAACI statementAllergyForthcoming2020 38SimonDWollenbergARenzHSimonHUAtopic dermatitis:"/>
 <result pre="Internationale Allergologicum (CIA) update 2019Int Arch Allergy Immunol201917820721830739107 39SeegrÃ¤berMWormMWerfelTSvenssonANovakNSimonDet al.Recurrent" exact="eczema" post="herpeticum - a retrospective European multicenter study evaluating the"/>
 <result pre="a retrospective European multicenter study evaluating the clinical characteristics of" exact="eczema" post="herpeticum cases in atopic dermatitis patientsJ Eur Acad Dermatol"/>
 <result pre="study evaluating the clinical characteristics of eczema herpeticum cases in" exact="atopic dermatitis" post="patientsJ Eur Acad Dermatol Venereol2020341074107931733162 40FerrucciSRomagnuoloMAngileriLBertiETavecchioSSafety of dupilumab in"/>
 <result pre="evaluating the clinical characteristics of eczema herpeticum cases in atopic" exact="dermatitis" post="patientsJ Eur Acad Dermatol Venereol2020341074107931733162 40FerrucciSRomagnuoloMAngileriLBertiETavecchioSSafety of dupilumab in"/>
 <result pre="patientsJ Eur Acad Dermatol Venereol2020341074107931733162 40FerrucciSRomagnuoloMAngileriLBertiETavecchioSSafety of dupilumab in severe" exact="atopic dermatitis" post="and infection of COVID-19: two case reportsJ Eur Acad"/>
 <result pre="Eur Acad Dermatol Venereol2020341074107931733162 40FerrucciSRomagnuoloMAngileriLBertiETavecchioSSafety of dupilumab in severe atopic" exact="dermatitis" post="and infection of COVID-19: two case reportsJ Eur Acad"/>
 <result pre="Dermatol Venereol2020341074107931733162 40FerrucciSRomagnuoloMAngileriLBertiETavecchioSSafety of dupilumab in severe atopic dermatitis and" exact="infection" post="of COVID-19: two case reportsJ Eur Acad Dermatol VenereolForthcoming2020"/>
 <result pre="Eur Acad Dermatol VenereolForthcoming2020 41BernsteinJALangDMKhanDACraigTDreyfusDHsiehFet al.The diagnosis and management of" exact="acute" post="and chronic urticaria: 2014 updateJ Allergy Clin Immunol20141331270127724766875 42ZhouFYuTDuRFanGLiuYLiuZet"/>
 <result pre="Dermatol VenereolForthcoming2020 41BernsteinJALangDMKhanDACraigTDreyfusDHsiehFet al.The diagnosis and management of acute and" exact="chronic" post="urticaria: 2014 updateJ Allergy Clin Immunol20141331270127724766875 42ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course"/>
 <result pre="Immunol20141331270127724766875 42ZhouFYuTDuRFanGLiuYLiuZet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
</results>
